EMA Authorised: Temodal (temozolomide) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA authorised Temodal (temozolomide) for glioma, with Merck Sharp & Dohme B.V. as the marketing authorisation holder; decision date 06/11/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma
• Glioma

Drugs mentioned

• Temodal (temozolomide)

Snippet

Status: Authorised. Therapeutic area: Glioma. MAH: Merck Sharp & Dohme B.V.. Decision date: 06/11/2025